Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimal Treatment Duration of Pegasys + Ribavirin in Chronic Hepatitis C
NCT02641379Phase 4Completed
- Sponsor
- Roche
- Start
- May 2003
- Primary completion
- Nov 2013
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
A Phase 4 trial of peginterferon alfa-2a in hepatitis C (HCV), sponsored by Roche. Started May 2003; status: completed.
02
Drugs
peginterferon alfa-2a
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02641379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02641379.